Testosterone deficiency in men with end stage renal disease and kidney transplantation: a narrative review.

Testosterone deficiency is highly prevalent in men with end-stage renal disease.

• Prevalence of hypogonadism in ESRD patients ranges from 40% to 66% across studies reviewed.
• Uremia associated with ESRD disrupts the hypothalamic-pituitary-gonadal (HPG) axis, contributing to testosterone deficiency.
• Both primary and secondary hypogonadism mechanisms are implicated in ESRD patients.
• Elevated prolactin levels in uremic patients further suppress gonadotropin release and testosterone production.

Renal transplantation does not reliably restore normal testosterone levels in men with prior ESRD.

• Many patients continue to have testosterone deficiency following renal transplantation despite restoration of renal function.
• Immunosuppressive medications used post-transplant, including calcineurin inhibitors and corticosteroids, contribute to ongoing hypogonadism.
• Corticosteroids suppress the HPG axis and impair Leydig cell function.
• Some studies report partial recovery of testosterone levels post-transplant, but normalization is inconsistent across patient populations.

Testosterone deficiency in ESRD and transplant patients negatively impacts sexual and erectile function.

• Erectile dysfunction is highly prevalent in ESRD patients, with reported rates exceeding 50% in some series.
• Low testosterone contributes to reduced libido, erectile dysfunction, and impaired sexual satisfaction.
• Renal transplantation may improve but does not fully resolve sexual dysfunction in many patients.
• The multifactorial etiology of erectile dysfunction in this population includes vascular, neurogenic, and hormonal components.

Testosterone deficiency adversely affects bone mineral density in ESRD and renal transplant patients.

• ESRD patients are at significantly elevated risk for renal osteodystrophy, which is compounded by hypogonadism.
• Low testosterone contributes to decreased bone mineral density (BMD) and increased fracture risk.
• Post-transplant bone loss is accelerated by corticosteroid use and persistent hypogonadism.
• Testosterone plays a role in bone metabolism through direct androgen receptor signaling and aromatization to estradiol.

Testosterone deficiency is associated with anemia in ESRD patients.

• Testosterone stimulates erythropoiesis through upregulation of erythropoietin production and direct effects on bone marrow.
• Low testosterone levels in ESRD contribute to worsening anemia beyond the effects of reduced erythropoietin from damaged kidneys.
• TRT has been shown to improve hemoglobin levels and reduce erythropoiesis-stimulating agent (ESA) requirements in some studies.
• The erythropoietic effects of testosterone may be particularly relevant in dialysis-dependent ESRD patients.

Testosterone replacement therapy appears to be safe and beneficial in ESRD and renal transplant patients.

• TRT demonstrated improvements in sexual function, BMD, anemia, and quality of life across reviewed studies.
• No significant adverse effects on graft survival or renal function were reported in transplant patients receiving TRT.
• TRT was associated with reductions in ESA requirements in hemodialysis patients in several studies.
• The authors note the evidence base is limited by small sample sizes and lack of large randomized controlled trials.

Potential effects of testosterone deficiency and TRT on graft survival following renal transplantation require further study.

• Testosterone has immunomodulatory properties that may theoretically influence allograft outcomes.
• Some evidence suggests testosterone deficiency may be associated with worse graft survival, though data are limited.
• TRT did not appear to increase rejection rates in available studies, suggesting immunological safety in transplant recipients.
• The authors emphasize that the relationship between testosterone levels and graft survival remains incompletely characterized.

There is a critical need for larger, high-quality prospective studies on TRT in ESRD and renal transplant populations.

• Current evidence is predominantly from small, retrospective, or observational studies with significant methodological limitations.
• The authors call for standardized screening protocols for testosterone deficiency in ESRD and transplant patients.
• Optimal TRT formulation, dosing, and duration in this population remain undefined.
• Proactive screening and treatment of testosterone deficiency 'may prove beneficial, emphasizing the urgency for further research in this area.'